Dr. Jay Chong Wang, MD

Dr. Wang practices at Northern California Retina Vitreous Associates Medical Group, Inc. in Mountain View, California.

Dr. Wang's NPI, 1225443997, was assigned on June 21, 2014. Dr. Wang graduated from Harvard Medical School in 2014. Dr. Wang's California license number on file is A174746.

Dr. Wang's primary practice is Northern California Retina Vitreous Associates Medical Group, Inc., at 2485 Hospital Dr, Mountain View, CA 94040 in Santa Clara County. The practice phone is (650) 963-3460.

Dr. Wang's primary practice is Northern California Retina Vitreous Associates Medical Group, Inc. in Mountain View, California. Dr. Wang is also affiliated with Zuckerberg San Francisco General Hospital and Trauma Center. The medical group on file is UCSF Department of Radiology & Biomedical Imaging. Dmand AI also links Dr. Wang to 1 more hospital, 2 medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wang practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Wang's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Wang is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Wang's licenses on file in 3 states: California, Connecticut and Massachusetts.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, dry eye, glaucoma, inflammation of iris, laser destruction of retinal or choroid lesions and retinal detachment among the conditions Dr. Wang treats.

CMS data shows 41,125 Medicare services from Dr. Wang across 14 procedure codes in 2024, for 877 Medicare patients. Medicare paid $2,420,522 for them. Every service was in an office.

CMS counts 877 Medicare patients who saw Dr. Wang in 2024. The largest group is 65 to 74, with 322 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.39, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Wang's median patient age at 70, with 54% women.

In 2024, Dr. Wang wrote 434 Medicare Part D claims for 112 patients. 68% of them were for generic drugs. CMS names the drug for 381 of them, across 7 drugs with 11 or more claims each, at $12,348 in total drug cost. In 2023, CMS named 378 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Wang for performance year 2024, reported as part of a group. Dr. Wang accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 68 papers to Dr. Wang, published from 2011 to 2025. 2020 was the busiest year, with 13. The most frequent topics are Tomography, Optical Coherence, Fluorescein Angiography and Visual Acuity. Dr. Wang has published most often in Br J Ophthalmol. Dr. Wang's most frequent co-authors are Deeba Husain, MD, Dean Eliott, MD and Leo Am Kim, MD, PhD.

CMS Open Payments shows 86 general payments to Dr. Wang from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 52% of the total. Genentech, Inc. paid the most, $8,350. It also lists 6 research payments totaling $802 in 2025, naming 1 clinical trial.

Dr. Wang graduated from Harvard Medical School in 2014.

Dr. Wang is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.